Tu Nguyen-Ngoc

Tu Nguyen-Ngoc

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MAMarion Arnaud
Marion Arnaud
JCJohanna Chiffelle
Johanna Chiffelle
RGRaphael Genolet
Raphael Genolet
BRBlanca Navarro Rodrigo
Blanca Navarro Rodrigo
MPMarta A. S. Perez
Marta A. S. Perez
AHAlexandre Harari
Alexandre Harari
The identification of patient-specific tumor antigens is complicated by the low frequency of T cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables the sensitive identification of rare tumor (neo)antigens and of cognate T cell receptors (TCRs) expressed by tumor-infiltrating lymphocytes. T cells transduced with tumor antigen-specific TCRs identified by NeoScreen mediate regression of established tumors in patient-derived xenograft mice.

6 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJulien Schmidt
Julien Schmidt
JCJohanna Chiffelle
Johanna Chiffelle
MPMarta A. S. Perez
Marta A. S. Perez
MMMorgane Magnin
Morgane Magnin
SBSara Bobisse
Sara Bobisse
AHAlexandre Harari
Alexandre Harari
The success of cancer immunotherapy depends in part on the strength of antigen recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen sensitivity) and structural (monomeric pMHC-TCR off-rates) avidities of 371 CD8 T cell clones specific for neoantigens, tumor-associated antigens (TAAs) or viral antigens isolated from tumors or blood of patients and healthy donors. T cells from tumors exhibit stronger functional and structural avidity than their blood counterparts. Relative to TAA, neoantigen-specific T cells are of higher structural avidity and, consistently, are preferentially detected in tumors. Effective tumor infiltration in mice models is associated with high structural avidity and CXCR3 expression. Based on TCR biophysicochemical properties, we derive and apply an in silico model predicting TCR structural avidity and validate the enrichment in high avidity T cells in patients’ tumors. These observations indicate a direct relationship between neoantigen recognition, T cell functionality and tumor infiltration. These results delineate a rational approach to identify potent T cells for personalized cancer immunotherapy.

23 December 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
GBGaylor Boulay
Gaylor Boulay
LCLuisa Cironi
Luisa Cironi
SGSara P Garcia
Sara P Garcia
SRShruthi Rengarajan
Shruthi Rengarajan
YXYu-Hang Xing
Yu-Hang Xing
NRNicolò Riggi
Nicolò Riggi
Synovial sarcoma (SyS) is an aggressive mesenchymal malignancy invariably associated with the chromosomal translocation t(X:18; p11:q11), which results in the in-frame fusion of the BAF complex gene SS18 to one of three SSX genes. Fusion of SS18 to SSX generates an aberrant transcriptional regulator, which, in permissive cells, drives tumor development by initiating major chromatin remodeling events that disrupt the balance between BAF-mediated gene activation and polycomb-dependent repression. Here, we developed SyS organoids and performed genome-wide epigenomic profiling of these models and mesenchymal precursors to define SyS-specific chromatin remodeling mechanisms and dependencies. We show that SS18-SSX induces broad BAF domains at its binding sites, which oppose polycomb repressor complex (PRC) 2 activity, while facilitating recruitment of a non-canonical (nc)PRC1 variant. Along with the uncoupling of polycomb complexes, we observed H3K27me3 eviction, H2AK119ub deposition and the establishment of de novo active regulatory elements that drive SyS identity. These alterations are completely reversible upon SS18-SSX depletion and are associated with vulnerability to USP7 loss, a core member of ncPRC1.1. Using the power of primary tumor organoids, our work helps define the mechanisms of epigenetic dysregulation on which SyS cells are dependent.

1 December 2023 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
ASAntonia Stamatiou
Antonia Stamatiou
TNTu Nguyen-Ngoc
Tu Nguyen-Ngoc
LWLaureline Wetterwald
Laureline Wetterwald
ADAna Dolcan
Ana Dolcan
GTGiovanni Dei Tos
Giovanni Dei Tos
ADAntonia Digklia
Antonia Digklia
Tenosynovial giant cell tumor (TGCT) is a rare and locally aggressive benign tumor arising from the synovium of joints, bursae, and tendon sheaths. It is classified into localized (L-TGCT) and diffuse (D-TGCT) forms based on the extent of involvement. Surgical resection is the primary treatment, though achieving a definitive cure remains challenging due to the high recurrence rates, especially in D-TGCT. Systemic therapies targeting the CSF1-CSF1R axis have emerged as promising treatment options. CSF1R tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, pexidartinib, and vimseltinib, alongside anti-CSF1R antibodies like emactuzumab, cabiralizumab, and lacnotuzumab, have shown encouraging results in managing TGCT, particularly when surgery is not feasible or poses significant morbidity. Other potential therapies, including local treatments and anti-inflammatory drugs, are being explored for TGCT management. This review provides an overview of systemic treatment options for D-TGCT, highlighting emerging therapeutic modalities and their potential implications. Effective management is crucial due to TGCT’s significant morbidity despite its non-life-threatening nature, necessitating novel approaches to improve patient prognosis and quality of life.

1 January 2022 in Revue Medicale Suisse
Verified
Journal Article
Open access
RSRoberta Stauber
Roberta Stauber
LSLouis Gro S
Louis Gro S
TNTu Nguyen-Ngoc
Tu Nguyen-Ngoc
NMNuria Mederos
Nuria Mederos
HBHasna Bouchaab
Hasna Bouchaab
KAKarim Abdelhamid
Karim Abdelhamid
Au cours de ces dernières années, de nouvelles stratégies thérapeutiques pour le cancer du poumon non à petites cellules (CPNPC) se sont développées, dé...